PCA3: From basic molecular science to the clinical lab

Cancer Letters

Volumn 301, Issue 1, 2011, Pages 1-6

  Day, John R ^a   Jost, Matthias ^a   Reynolds, Mark A ^a   Groskopf, Jack ^a   Rittenhouse, Harry ^a  

^a Gen Probe Incorporated   (United States)

Author keywords

DD3; Diagnostic; Marker; PCA3; Prostate cancer

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNTRANSLATED RNA;

CANCER MORTALITY; CANCER SCREENING; CHROMOSOME 9Q; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; GENE EXPRESSION; GENE LOCATION; GENETIC REGULATION; HIGH RISK PATIENT; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TUMOR GENE; UNITED STATES; URINALYSIS;

EID: 78650533827     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.019     Document Type: Review

References (42)

1. American Cancer Society, Cancer Facts & Figures, American Cancer Society, Atlanta, 2010.
2. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., Debruyne F.M., Ru N., Isaacs W.B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999, 59:5975-5979.
3. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., Swinkels D.W., Schalken J.A. DD3(PCA3), A very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002, 62:2695-2698.
4. Hessels D., Klein Gunnewiek J.M., van Oort I., Karthaus H.F., van Leenders G.J., van Balken B., Kiemeney L.A., Witjes J.A., Schalken J.A. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44:8-15.
5. Clarke R.A., Zhao Z., Guo A.Y., Roper K., Teng L., Fang Z.M., Samaratunga H., Lavin M.F., Gardiner R.A. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009, 4:e4995.
6. Salagierski M., Verhaegh G.W., Jannink S.A., Smit F.P., Hessels D., Schalken J.A. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate 2010, 70:70-78.
7. Schalken J.A., Hessels D., Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003, 62:34-43.
8. J.A. Schalken, personal communication.
9. J.S. Mattick, I.V. Makunin, Non-coding RNA, Human Mol. Genet. 15 Spec No. 1, 2006, pp. R17-29.
10. Szell M., Bata-Csorgo Z., Kemeny L. The enigmatic world of mRNA-like ncRNAs: their role in human evolution and in human diseases. Semin. Cancer Biol. 2008, 18:141-148.
11. Turner A.M., Morris K.V. Controlling transcription with noncoding RNAs in mammalian cells. BioTechniques 2010, 48:ix-xvi.
12. Srikantan V., Zou Z., Petrovics G., Xu L., Augustus M., Davis L., Livezey J.R., Connell T., Sesterhenn I.A., Yoshino K., Buzard G.S., Mostofi F.K., McLeod D.G., Moul J.W., Srivastava S. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 2000, 97:12216-12221.
13. Petrovics G., Zhang W., Makarem M., Street J.P., Connelly R., Sun L., Sesterhenn I.A., Srikantan V., Moul J.W., Srivastava S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004, 23:605-611.
14. Fu X., Ravindranath L., Tran N., Petrovics G., Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 2006, 25:135-141.
15. Meng F.J., Shan A., Jin L., Young C.Y. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol. Biomarkers Prev. 2002, 11:305-309.
16. van Gils M.P., Hessels D., van Hooij O., Jannink S.A., Peelen W.P., Hanssen S.L., Witjes J.A., Cornel E.B., Karthaus H.F., Smits G.A., Dijkman G.A., Mulders P.F., Schalken J.A. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 2007, 13:939-943.
17. Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., Masse B., Piche L., Chypre C. UPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004, 64:311-315.
18. Tinzl M., Marberger M., Horvath S., Chypre C. DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur. Urol. 2004, 46:182-186.
19. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., Brentano S., Mathis J., Pham J., Meyer T., Cass M., Hodge P., Macairan M.L., Marks L.S., Rittenhouse H. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 2006, 52:1089-1095.
20. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., Ellis W.J., Marks L.S., Fradet Y., Rittenhouse H., Groskopf J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 2008, 179:1587-1592.
21. Haese A., de la Taille A., van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Abbou C.C., Remzi M., Tinzl M., Feyerabend S., Stillebroer A.B., van Gils M.P., Schalken J.A. Clinical utility of the PCA3 urine assay in european men scheduled for repeat biopsy. Eur. Urol. 2008, 54:1081-1088.
22. Schilling D., Hennenlotter J., Munz M., Bokeler U., Sievert K.D., Stenzl A. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice. Urol. Int. 2010, 85:159-165.
23. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M., Cancio A.T., Desaulniers M., Ellis W.J., Rittenhouse H., Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69:532-535.
24. Vlaeminck-Guillem V., Ruffion A., Andre J., Devonec M., Paparel P. Urinary prostate cancer 3 test: toward the age of reason?. Urology 2010, 75:447-453.
25. Sokoll L.J., Ellis W., Lange P., Noteboom J., Elliott D.J., Deras I.L., Blase A., Koo S., Sarno M., Rittenhouse H., Groskopf J., Vessella R.L. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin. Chim. Acta 2008, 389:1-6.
26. Shappell S.B., Fulmer J., Arguello D., Wright B.S., Oppenheimer J.R., Putzi M.J. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009, 73:363-368.
27. van Gils M.P., Cornel E.B., Hessels D., Peelen W.P., Witjes J.A., Mulders P.F., Rittenhouse H.G., Schalken J.A. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007, 67:881-887.
28. Foot N.C., Papanicolaou G.N., Holmquist N.D., Seybolt J.F. Exfoliative cytology of urinary sediments; a review of 2, 829 cases. Cancer 1958, 11:127-137.
29. Varma V.A., Fekete P.S., Franks M.J., Walther M.M. Cytologic features of prostatic adenocarcinoma in urine: a clinicopathologic and immunocytochemical study. Diagnos. Cytopathol. 1988, 4:300-305.
30. Krishnan B., Truong L.D. Prostatic adenocarcinoma diagnosed by urinary cytology. Am. J. Clin. Pathol. 2000, 113:29-34.
31. L.G. Koss, Cytology of specimens obtained by prostatic massage, Diagnostic Cytology and its Histopathologic Bases, J.B. Lippincott Company, Philadelphia, 1992, pp. 1001-1005.
32. Bonkhoff H. Molecular diagnostics in prostate urine: interpret results correctly. Uro-News. 2009, 2:45-48.
33. Fujita K., Pavlovich C.P., Netto G.J., Konishi Y., Isaacs W.B., Ali S., De Marzo A., Meeker A.K. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. Human Pathol. 2009, 40:924-933.
34. Morote J., Rigau M., Garcia M., Mir C., Ballesteros C., Planas J., Raventos C.X., Placer J., de Torres I.M., Reventos J., Doll A. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J. Urol. 2010, 28:677-680.
35. Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., Breed S., Somerville M., Rittmaster R. And REDUCE Study Group, Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J. Urol. 2004, 172:1314-1317.
36. Aubin S.M., Reid J., Sarno M.J., Blase A., Aussie J., Rittenhouse H., Rittmaster R., Andriole G.L., Groskopf J. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J. Urol. 2010, 184:1947-1952.
37. Ankerst D.P., Groskopf J., Day J.R., Blase A., Rittenhouse H., Pollock B.H., Tangen C., Parekh D., Leach R.J., Thompson I. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J. Urol. 2008, 180:1303-1308.
38. Chun F.K., de la Taille A., van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Abbou C.C., Stillebroer A.B., van Gils M.P., Schalken J.A., Fradet Y., Marks L.S., Ellis W., Partin A.W., Haese A. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur. Urol. 2009, 56:659-667.
39. Auprich M., Haese A., Walz J., Pummer K., de la Taille A., Graefen M., de Reijke T., Fisch M., Kil P., Gontero P., Irani J., Chun F.K. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur. Urol. 2010, 58:727-732.
40. Nakanishi H., Groskopf J., Fritsche H.A., Bhadkamkar V., Blase A., Kumar S.V., Davis J.W., Troncoso P., Rittenhouse H., Babaian R.J. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 2008, 179:1804-1809.
41. Whitman E.J., Groskopf J., Ali A., Chen Y., Blase A., Furusato B., Petrovics G., Ibrahim M., Elsamanoudi S., Cullen J., Sesterhenn I.A., Brassell S., Rittenhouse H., Srivastava S., McLeod D.G. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 2008, 180:1975-1978.
42. Hessels D., van Gils M.P., van Hooij O., Jannink S.A., Witjes J.A., Verhaegh G.W., Schalken J.A. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010, 70:10-16.